Analytical Data
-
Gene name
Integrin beta-1/CD29
- Application
-
Alternative Names
CD29; MSK12; ITG-B1; FNRB; GPIIA; MDF2; MSK12; VLAB; Fibronectin Receptor Beta Polypeptide; Antigen CD29 Includes MDF2; Glycoprotein IIa; VLA-4 subunit beta
-
Species
Human
-
Source
E. coli
-
Tag
N- His & GST
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P05556
-
Expression Region
Asp140~Ile383
-
Molecular Weight
57kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Integrin beta-1, also known as CD29, is a crucial component of integrin receptors that mediate cell adhesion, migration, and signal transduction. Its involvement in various physiological and pathological processes, including embryogenesis, wound healing, and tumor progression, has garnered significant attention in biomedical research. The heterodimer formed by integrin beta-1 and its alpha partners facilitates interactions with the extracellular matrix (ECM) and other cell types, influencing cellular behavior and tissue organization. Research on recombinant integrin beta-1/CD29 proteins primarily aims to elucidate their structural and functional properties, as well as their roles in cell signaling pathways. These studies have significant implications for understanding diseases such as cancer, where altered integrin expression can affect tumor cell behavior and metastasis. Additionally, investigating recombinant forms of integrin beta-1 can aid in developing novel therapeutic strategies and biomaterials for regenerative medicine. Overall, the study of integrin beta-1/CD29 recombinant proteins is pivotal in advancing our knowledge of cell-matrix interactions and their implications in health and disease.
